Release of PACAP-38 in Episodic Cluster Headache Patients - an Exploratory Study

Overview

Journal J Headache Pain

Publisher Biomed Central

Date 2016 Aug 1

PMID 27475101

Citations 38

Authors

Bernadett Tuka

Nikoletta Szabo

Eszter Toth

Zsigmond Tamas Kincses

Arpad Pardutz

Delia Szok

Tamas Kortesi

Terez Bagoly

Zsuzsanna Helyes

Lars Edvinsson

Laszlo Vecsei

Janos Tajti

Affiliations

Soon will be listed here.

Abstract

Background: Activation of the trigeminal-autonomic reflex, involving the trigeminal ganglion, the superior salivatory nucleus and the sphenopalatine ganglion (SPG) is crucial in the pathophysiology of cluster headache (CH). Since pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) is present both in the SPG and the trigeminal ganglion (TG) and its role in migraine has been described, our aim was to determine the plasma PACAP-38 levels in different phases of episodic CH (ECH). Peripheral cubital fossa blood samples were taken during the ictal and inter-bout periods of male ECH patients and from age-matched healthy controls (n = 9). Plasma PACAP-38-like immunoreactivity (LI) was measured with specific and sensitive radioimmunoassay.

Findings: Significantly lower plasma PACAP-38-LI was detected in the inter-bout period of ECH patients than in healthy controls. However, PACAP-38 was significantly elevated in the plasma during CH attacks as compared to the inter-bout phase in the same subjects (n = 5).

Conclusions: This exploratory study suggests that PACAP-38 may be released during the attacks of ECH. Further patients and long-term follow-up are necessary to reveal its function.

Citing Articles

Cluster Headache and Hypoxia: Breathing New Life into an Old Theory, with Novel Implications.

Borkum J Neurol Int. 2024; 16(6):1691-1716.

PMID: 39728749 PMC: 11679651. DOI: 10.3390/neurolint16060123.

Current and Novel Therapies for Cluster Headache: A Narrative Review.

de Freitas Dias B, Robinson C, Villar-Martinez M, Ashina S, Goadsby P Pain Ther. 2024; 14(1):1-19.

PMID: 39489854 PMC: 11751248. DOI: 10.1007/s40122-024-00674-7.

Understanding the kynurenine pathway: A narrative review on its impact across chronic pain conditions.

Hazrati E, Eftekhar S, Mosaed R, Dini S, Namazi M Mol Pain. 2024; 20:17448069241275097.

PMID: 39093627 PMC: 11331475. DOI: 10.1177/17448069241275097.

Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.

Karsan N, Edvinsson L, Vecsei L, Goadsby P Ann Clin Transl Neurol. 2024; 11(7):1654-1668.

PMID: 38887982 PMC: 11251486. DOI: 10.1002/acn3.52119.

Research hotspots and frontiers of cluster headaches: a bibliometric analysis.

Mao Q, Xu S, Wang Y, Wu D, Huang G, Li Z Front Neurol. 2024; 15:1395770.

PMID: 38725643 PMC: 11079126. DOI: 10.3389/fneur.2024.1395770.

References

Goadsby P, Lipton R . A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain. 1997; 120 ( Pt 1):193-209. DOI: 10.1093/brain/120.1.193. View

Amin F, Hougaard A, Magon S, Asghar M, Ahmad N, Rostrup E . Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study. Neurology. 2015; 86(2):180-7. DOI: 10.1212/WNL.0000000000002261. View

Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, Szabo N . Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013; 33(13):1085-95. DOI: 10.1177/0333102413483931. View

Syed A, Koide M, Braas K, May V, Wellman G . Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine. J Mol Neurosci. 2012; 48(3):574-83. PMC: 3581331. DOI: 10.1007/s12031-012-9851-0. View

Grande G, Labruijere S, Haanes K, MaassenVanDenBrink A, Edvinsson L . Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds. J Headache Pain. 2014; 15:22. PMC: 4011837. DOI: 10.1186/1129-2377-15-22. View

Mulder H, Uddman R, Moller K, Zhang Y, Ekblad E, Alumets J . Pituitary adenylate cyclase activating polypeptide expression in sensory neurons. Neuroscience. 1994; 63(1):307-12. DOI: 10.1016/0306-4522(94)90025-6. View

Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L . Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999; 76(2-3):176-83. DOI: 10.1016/s0165-1838(99)00024-7. View

Eftekhari S, Salvatore C, Johansson S, Chen T, Zeng Z, Edvinsson L . Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res. 2014; 1600:93-109. DOI: 10.1016/j.brainres.2014.11.031. View

Zagami A, Edvinsson L, Goadsby P . Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol. 2015; 1(12):1036-40. PMC: 4284128. DOI: 10.1002/acn3.113. View

10.

Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L, Warfvinge K . Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Neuroscience. 2011; 202:158-68. DOI: 10.1016/j.neuroscience.2011.10.055. View

11.

Schytz H, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M . PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2008; 132(Pt 1):16-25. DOI: 10.1093/brain/awn307. View

12.

Goadsby P, Edvinsson L . Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994; 117 ( Pt 3):427-34. DOI: 10.1093/brain/117.3.427. View

13.

Schytz H, Holst H, Arendt-Nielsen L, Olesen J, Ashina M . Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. J Headache Pain. 2010; 11(4):309-16. PMC: 3476346. DOI: 10.1007/s10194-010-0214-3. View

14.

Eftekhari S, Warfvinge K, Blixt F, Edvinsson L . Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013; 14(11):1289-303. DOI: 10.1016/j.jpain.2013.03.010. View

15.

Uddman R, Tajti J, Moller S, Sundler F, Edvinsson L . Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res. 1999; 826(2):193-9. DOI: 10.1016/s0006-8993(99)01260-3. View

16.

Nicolodi M, Del Bianco E . Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache. Cephalalgia. 1990; 10(1):39-50. DOI: 10.1046/j.1468-2982.1990.1001039.x. View

17.

Tuka B, Helyes Z, Markovics A, Bagoly T, Nemeth J, Mark L . Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system. Peptides. 2012; 33(2):307-16. DOI: 10.1016/j.peptides.2011.12.019. View

18.

Donnet A, Lanteri-Minet M, Guegan-Massardier E, Mick G, Fabre N, Geraud G . Chronic cluster headache: a French clinical descriptive study. J Neurol Neurosurg Psychiatry. 2007; 78(12):1354-8. PMC: 2095607. DOI: 10.1136/jnnp.2006.112037. View

19.

Fahrenkrug J, Hannibal J . Neurotransmitters co-existing with VIP or PACAP. Peptides. 2004; 25(3):393-401. DOI: 10.1016/j.peptides.2004.01.010. View

20.

Palkovits M, Somogyvari-Vigh A, Arimura A . Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei. Brain Res. 1995; 699(1):116-20. DOI: 10.1016/0006-8993(95)00869-r. View